Spontaneous venous thrombosis in a young patient with combined factor V Leiden and lupus anticoagulant

American Journal of Hematology

Volumn 62, Issue 1, 1999, Pages 58-60

  Lopez, Francisco F ^a   Sweeney, Joseph D ^a,b   Blair, Abbe J ^a   Sikov, William M ^a  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

Factor V Leiden; Lupus anticoagulant; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT;

ADULT; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; FAMILY HISTORY; HETEROZYGOSITY; HUMAN; MALE; MUTATION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOPHILIA;

ADULT; ANTIPHOSPHOLIPID SYNDROME; FACTOR V; GENETIC SCREENING; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; PEDIGREE; SMOKING; THROMBOPHILIA; THROMBOPHLEBITIS; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 0032880587     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199909)62:1<58::AID-AJH11>3.0.CO;2-0     Document Type: Article

References (12)

1. Svensson PJ, Dahlback B: Resistance to activated protein C as basis for venous thrombosis. N Engl J Med 1994;330:1512-1562.
2. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J: Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685-3691.
3. Ginsburg KS, Liang MH, Newcomer L, et al.: Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Inter Med. 1992;117:997-1002.
4. Dumenco L, Blair A, Sweeney JD: The results of diagnostic studies for thrombophilia in a large group of patients with personal or family history of thrombosis. Am J Clin Pathol 1998;110:673-682.
5. Koeleman B, Reitsma P, Allaart C, Bertina M: Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 1994;84:1031-1035.
6. Koeleman B, van Rumpt D, Hamulyak K, Reitsma P, Bertina R: Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995;74:580-583.
7. Vandenbroucke J, Koster T, Briet E, Reitsma P, Bertina R, Rosendaal FR: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457.
8. Rosendaal F, Siscovick S, Schwartz S, Beverly R, Psaty B, Longstreth Jr W, Raghunathan T, Koepsell T, Reitsma P: Factor V Leiden (Resistance to Activated Protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-2821.
9. Simioni P, Prandoni P, Lensing A, et al.: The risk of recurrent venous thromboembolism in patients with an Ard 506-Gln mutation in the gene for factor V Leiden. N Engl J Med 1997;336:399-403.
10. Mandel H, Brenner B, Berant M, Rosenberg N, et al.: Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis. N Engl J Med 1996;334:763-768.
11. den Heijer M, Koster T, Blom H, et al.: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
12. Middeldrop S, Henkens C, Koopman M, et al.: The incidence of venous thromboembolism in family members of patients with factor V Leiden Mutation and venous thrombosis. Ann Intern Med 1998;128: 15-20.